Baseline characteristics of the X-ray completer cohort randomised to secukinumab at baseline
| Characteristic | Secukinumab intravenous 150 mg (n=86) | Secukinumab intravenous 75 mg (n=82) |
|---|---|---|
| Age, mean (SD) years | 39.6 (12.0) | 42.4 (13.1) |
| Male gender, n (%) | 63 (73.3) | 60 (73.2) |
| Weight, mean (SD) kg | 75.2 (16.4) | 78.4 (19.3) |
| Time since AS diagnosis, mean (SD) years | 6.6 (7.0) | 7.8 (8.9) |
| HLA-B27 positive, n (%) | 64 (74.4) | 72 (87.8) |
| Current smoker, n (%) | 25 (29.1) | 17 (20.7) |
| Anti-TNF-naive, n (%) | 60 (69.8) | 62 (75.6) |
| Medication use at baseline, n (%) | ||
| Methotrexate | 14 (16.3) | 12 (14.6) |
| Sulfasalazine | 27 (31.4) | 32 (39.0) |
| Glucocorticoids | 13 (15.1) | 10 (12.2) |
| hsCRP, median (min, max), mg/L | 7.8 (0.2, 147.7) | 9.7 (0.4, 100.0) |
| Elevated hsCRP >5 mg/L, n (%) | 55 (64.0) | 50 (61.0) |
| Total BASDAI, mean (SD) | 6.2 (1.6) | 6.0 (1.5) |
| BASFI, mean (SD) | 5.6 (2.2) | 5.4 (2.0) |
| BASMI (linear), mean (SD) | 3.9 (1.8) | 4.2 (1.7) |
| mSASSS, mean (SD) | 9.6 (16.6) | 10.8 (16.7) |
| Syndesmophyte present, n (%) | 51 (59.3) | 53 (64.6) |
| Total back pain, mean (SD) | 63.9 (17.2) | 63.3 (18.6) |
| Patient's global assessment of disease activity, mean (SD) | 64.6 (17.7) | 60.5 (18.6) |
Data are n (%), mean (SD), or median (minimum–maximum).
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; HLA, human leucocyte antigen; hsCRP, high-sensitivity C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; TNF, tumour necrosis factor.